Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.0
4.2
Journals
Biology
Special Issues
Role of the Immune System in Cancer
share announcement

Role of the Immune System in Cancer

A special issue of Biology (ISSN 2079-7737). This special issue belongs to the section "Immunology".

Deadline for manuscript submissions: closed (28 February 2022) | Viewed by 9499

Special Issue Editors

Dr. Ana Igea

E-Mail Website
Guest Editor
Biomedical Research Centre (CINBIO), University of Vigo, 36310 Vigo, Spain
Interests: breast cancer; colorectal cancer; pancreatic cancer; immunotherapy
Dr. Ioannis Pateras

E-Mail Website
Guest Editor
2nd Department of Pathology, “Attikon” University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece
Interests: pathology; cancer pathology; colorectal cancer; lung cancer; pancreatic cancer; breast cancer; inflammation; infectious agents; cell cycle; metabolism
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Over the past few years, we have learnt that cancer is extending beyond neoplastic cells to surround stroma, collectively called tumor microenvironment (TME). TME is created by the tumor cells and dominated by tumor-induced interactions that play a very important role in supporting tumor growth, neovascularization, invasion, metastasis and immune escape.

Successive changes occurring at the tumor site during tumor progression resemble chronic inflammation reaction. This inflammatory reaction seems to be orchestrated by the tumor that activates one or several mechanisms, leading to the inhibition of the anti-tumor function of the immune cells and promoting tumor growth and survival. The complexity of these interactions and the heterogeneity of the immune cell populations recruited in the TME are a real challenge when developing new immune-based therapies. The ultimate goal of immunotherapies is to rejuvenate host immunity against cancer. Hence, a better understanding of cellular and molecular pathways operating in the TME is necessary.

In this Special Issue, entitled “Role of the Immune System in Cancer”, we invite the submission of original research, brief research, clinical trials, case or data reports, systematic reviews, mini reviews, hypotheses, opinions or commentaries and perspectives.

Dr. Ana Igea
Dr. Ioannis Pateras
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • tumor microenvironment
  • immune-based therapies
  • onco-immunology
  • macrophages
  • lymphocytes
  • tumor
  • cancer
  • immune cross-talk

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 5968 KiB  
Article
MicroRNA-200c Attenuates the Tumor-Infiltrating Capacity of Macrophages
by Rebecca Raue, Ann-Christin Frank, Dominik C. Fuhrmann, Patricia de la Cruz-Ojeda, Silvia Rösser, Rebekka Bauer, Giulia Cardamone, Andreas Weigert, Shahzad Nawaz Syed, Tobias Schmid and Bernhard Brüne
Biology 2022, 11(3), 349; https://doi.org/10.3390/biology11030349 - 22 Feb 2022
Cited by 9 | Viewed by 2610
Abstract
Macrophages constitute a major part of the tumor-infiltrating immune cells. Within the tumor microenvironment, they acquire an alternatively activated, tumor-supporting phenotype. Factors released by tumor cells are crucial for the recruitment of tumor-associated macrophages. In the present project, we aimed to understand the [...] Read more.
Macrophages constitute a major part of the tumor-infiltrating immune cells. Within the tumor microenvironment, they acquire an alternatively activated, tumor-supporting phenotype. Factors released by tumor cells are crucial for the recruitment of tumor-associated macrophages. In the present project, we aimed to understand the role of hsa-miR-200c-3p (miR-200c) in the interplay between tumor cells and macrophages. To this end, we employed a coculture system of MCF7 breast tumor cells and primary human macrophages and observed the transfer of miR-200c from apoptotic tumor cells to macrophages, which required intact CD36 receptor in macrophages. We further comprehensively determined miR-200c targets in macrophages by mRNA-sequencing and identified numerous migration-associated mRNAs to be downregulated by miR-200c. Consequently, miR-200c attenuated macrophage infiltration into 3-dimensional tumor spheroids. miR-200c-mediated reduction in infiltration further correlated with a miR-200c migration signature comprised of the four miR-200c-repressed, predicted targets PPM1F, RAB11FIB2, RDX, and MSN. Full article
(This article belongs to the Special Issue Role of the Immune System in Cancer)
►▼ Show Figures

Figure 1

Review

Jump to: Research

13 pages, 5928 KiB  
Review
GARP: A Key Target to Evaluate Tumor Immunosuppressive Microenvironment
by Alexanne Bouchard, Bertrand Collin, Carmen Garrido, Pierre-Simon Bellaye and Evelyne Kohli
Biology 2021, 10(9), 836; https://doi.org/10.3390/biology10090836 - 27 Aug 2021
Cited by 9 | Viewed by 3259
Abstract
Glycoprotein-A repetitions predominant (GARP) is the docking receptor for latent transforming growth factor (LTGF-β) and promotes its activation. In cancer, increased GARP expression has been found in many types of cancer. GARP is expressed by regulatory T cells and platelets in the tumor [...] Read more.
Glycoprotein-A repetitions predominant (GARP) is the docking receptor for latent transforming growth factor (LTGF-β) and promotes its activation. In cancer, increased GARP expression has been found in many types of cancer. GARP is expressed by regulatory T cells and platelets in the tumor microenvironment (TME) and can be also expressed by tumor cells themselves. Thus, GARP can be widely present in tumors in which it plays a major role in the production of active TGF-β, contributing to immune evasion and cancer progression via the GARP-TGF-β pathway. The objective of this review is to highlight GARP expression and function in cancer and to evaluate the potential of membrane GARP as a predictive and therapeutic follow-up biomarker that could be assessed, in real time, by molecular imaging. Moreover, as GARP can be secreted, a focus will also be made on soluble GARP as a circulating biomarker. Full article
(This article belongs to the Special Issue Role of the Immune System in Cancer)
►▼ Show Figures

Figure 1

17 pages, 380 KiB  
Review
Inborn Errors of Immunity and Cancer
by Alessandra Tiri, Riccardo Masetti, Francesca Conti, Anna Tignanelli, Elena Turrini, Patrizia Bertolini, Susanna Esposito and Andrea Pession
Biology 2021, 10(4), 313; https://doi.org/10.3390/biology10040313 - 9 Apr 2021
Cited by 15 | Viewed by 2815
Abstract
Inborn Errors of Immunity (IEI) are a heterogeneous group of disorders characterized by a defect in the function of at least one, and often more, components of the immune system. The aim of this narrative review is to discuss the epidemiology, the pathogenesis [...] Read more.
Inborn Errors of Immunity (IEI) are a heterogeneous group of disorders characterized by a defect in the function of at least one, and often more, components of the immune system. The aim of this narrative review is to discuss the epidemiology, the pathogenesis and the correct management of tumours in patients with IEI. PubMed was used to search for all of the studies published over the last 20 years using the keywords: “inborn errors of immunity” or “primary immunodeficiency” and “cancer” or “tumour” or “malignancy”. Literature analysis showed that the overall risk for cancer in children with IEI ranges from 4 to 25%. Several factors, namely, age of the patient, viral infection status and IEI type can influence the development of different cancer types. The knowledge of a specific tumour risk in the presence of IEI highlights the importance of a synergistic effort by immunologists and oncologists in tracking down the potential development of cancer in known IEI patients, as well as an underlying IEI in patients with newly diagnosed cancers. In the current genomic era, the creation of an international registry of IEI cases integrated with malignancies occurrence information is fundamental to optimizing the diagnostic process and to evaluating the outcomes of new therapeutic options, with the hope to obtain a better prognosis for these patients. Full article
(This article belongs to the Special Issue Role of the Immune System in Cancer)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop